Cash flow Chongqing Zhifei Biological Products Co., Ltd.
Equities
300122
CNE100000V20
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.03 CNY | -1.22% |
|
+1.54% | -4.83% |
Dec. 09 | Chongqing Zhifei Biological, GSK Adjust Terms of Cooperation Agreement | MT |
Dec. 05 | GSK, China's Zhifei Extend Shingles Shot Collaboration to 2034 | DJ |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 2.37B | 3.3B | 10.21B | 7.54B | 8.07B | |||||
Depreciation & Amortization - CF | 76.14M | 107M | 264M | 275M | 303M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 11.9M | 13.23M | 111M | 38.57M | 17.87M | |||||
Depreciation & Amortization, Total | 88.04M | 120M | 375M | 313M | 321M | |||||
Amortization of Deferred Charges, Total - (CF) | 8.52M | 11.05M | 14.15M | 17.73M | 17.65M | |||||
(Gain) Loss From Sale Of Asset | -785 | -19.65K | -39.13K | -6.69K | -41.37M | |||||
(Gain) Loss on Sale of Investments - (CF) | - | - | 20.03M | - | - | |||||
Asset Writedown & Restructuring Costs | 86.96M | 549K | 1.68M | 92.8K | 129K | |||||
Provision and Write-off of Bad Debts | - | 82.93M | 191M | 421M | 353M | |||||
Other Operating Activities, Total | 75.26M | 184M | 134M | 166M | 394M | |||||
Change In Accounts Receivable | -2.53B | -2.25B | -6.55B | -8.06B | -6.76B | |||||
Change In Inventories | -730M | -975M | -3.98B | -766M | -1.31B | |||||
Change In Accounts Payable | 2.01B | 3.06B | 8.06B | 2.41B | 8.34B | |||||
Change In Deferred Taxes | -2.2M | -44.52M | 27.28M | -58.31M | -386M | |||||
Cash from Operations | 1.37B | 3.5B | 8.51B | 1.99B | 9B | |||||
Capital Expenditure | -573M | -827M | -1.93B | -1.45B | -1.13B | |||||
Sale of Property, Plant, and Equipment | 198K | 101K | 325K | 647K | 168M | |||||
Investment in Marketable and Equity Securities, Total | -50M | -70M | -69M | -45.5M | -10.5M | |||||
Other Investing Activities, Total | - | - | -18.55M | - | - | |||||
Cash from Investing | -623M | -897M | -2.02B | -1.5B | -977M | |||||
Short Term Debt Issued, Total | 3.31B | 6.65B | 94.63M | 39.08M | 5.54M | |||||
Long-Term Debt Issued, Total | - | - | 2.57B | 5.48B | 6.34B | |||||
Total Debt Issued | 3.31B | 6.65B | 2.66B | 5.52B | 6.35B | |||||
Short Term Debt Repaid, Total | -2.82B | -8.03B | -75.01M | -18.64M | -390K | |||||
Long-Term Debt Repaid, Total | - | - | -5.31B | -6.64B | -9.74B | |||||
Total Debt Repaid | -2.82B | -8.03B | -5.39B | -6.66B | -9.74B | |||||
Common Dividends Paid | -800M | -929M | -862M | -1.01B | -889M | |||||
Common & Preferred Stock Dividends Paid | -800M | -929M | -862M | -1.01B | -889M | |||||
Other Financing Activities, Total | -85.11M | 195M | -4.76M | -12.82M | -13.08M | |||||
Cash from Financing | -393M | -2.11B | -3.59B | -2.17B | -4.29B | |||||
Foreign Exchange Rate Adjustments | 851K | -4.93M | -9.66M | 17.56M | -2.3M | |||||
Net Change in Cash | 352M | 481M | 2.89B | -1.66B | 3.72B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 791M | - | - | - | - | |||||
Cash Income Tax Paid (Refund) | 733M | 875M | 1.95B | 3.27B | 3.31B | |||||
Levered Free Cash Flow | -1.13B | -96.68M | 2.89B | -3.93B | 1.49B | |||||
Unlevered Free Cash Flow | -1.08B | -17.22M | 2.92B | -3.9B | 1.54B | |||||
Change In Net Working Capital | 2.4B | 1.83B | 2.99B | 8.21B | 3.41B | |||||
Net Debt Issued / Repaid | 492M | -1.38B | -2.72B | -1.14B | -3.39B |